Eczema Research Study
Researchers at Children’s Hospital Los Angeles are conducting a study in children and adults ages 6 and older to learn more about different skin characteristics with eczema (atopic dermatitis).
Fast Facts
Moderate-Severe Eczema
6+ Years Old
Compensation Provided
Conducted in Los Angeles, CA
Study Background
This research study is being done to learn about certain characteristics of the skin and how these skin characteristics are related to the severity of eczema (atopic dermatitis) and the skin’s response to treatment.
Atopic dermatitis (AD), also called eczema, is a disease with dry, scaly, itchy skin. AD can produce differing levels of symptoms depending on the person. Some symptoms that can differ include:
- Itching
- Bacterial staph infections
- How long AD lasts
- Age you get it
- Response to medication
- Other associated conditions (including food allergy and asthma)
These differences suggest that there are different markers which may be related to AD severity which could predict how someone will respond to a certain treatment.
Study Background
This research study is being done to learn about certain characteristics of the skin and how these skin characteristics are related to the severity of eczema (atopic dermatitis) and the skin’s response to treatment.
Atopic dermatitis (AD), also called eczema, is a disease with dry, scaly, itchy skin. AD can produce differing levels of symptoms depending on the person. Some symptoms that can differ include:
- itching
- bacterial staph infections
- how long AD lasts
- age you get it
- response to medication
- other associated conditions (including food allergy and asthma)
These differences suggest that there are different markers which may be related to AD severity which could predict how someone will respond to a certain treatment.
Additional Information
In this research study, we want to look at how different gene expressions in the skin are associated with symptoms of eczema. This may help future researchers better predict how certain people will respond to certain eczema treatments.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- 6+ years old
- Moderate-severe eczema (atopic dermatitis)
- No other skin diseases
Exclusion Criteria:
- Known hypersensitivity to vanicream, hydrocortisone, triamcinolone, or dupilumab
- Chronic infections
- Pregnancy or breastfeeding
- Past treatments other than dupilumab
- Significant medical problems
- Significant drug or alcohol use
- Family or household member already enrolled in the study
- Planned surgical procedures
- History of cancer in the past 5 years
Depending on your clinical group assignment and treatment course, you will complete up to 10 scheduled study visits. Participation could be as short as 175 days (24 weeks) or as long as 231 days (32 weeks).
Study visits include:
- Vitals
- Blood draws
- Pregnancy tests (if applicable)
- Photographs of selected target skin area
- Skin sample collection
- Skin biopsies for participants 18 years and older
If you are already using dupilumab, you will continue to use dupilumab as it was prescribed to you by your doctor. If you qualify for dupilumab, you will receive dupilumab either every 2 weeks or 4 weeks depending on your weight.
As a participant, you may receive compensation for your time, as well as the cost of transportation or parking.
There is no cost for you to participate in our research study.